Skip to main content

Signed · United Kingdom · Pharma and biotech

SenzaGen agrees to acquire Alcyomics.

SenzaGen, based in Lund, Sweden, signed an agreement on 28 October 2026 to acquire all shares in Alcyomics, a Newcastle-based provider of non-animal immunotoxicology testing for preclinical drug development. Completion is expected around 4 November 2026. It was signed on 28 October 2026. It had not completed by 29 October 2026.

SigningDay 100

Signing 28 October 2026

Buyer
SenzaGen AB (publ) ·Lund, Sweden
Target
Alcyomics Ltd ·Newcastle, United Kingdom
Type
Acquisition
Announced
28 October 2026
Signed
28 October 2026
Value
about GBP 2.12 million (initial price)
People
Not stated in the release
Last checked
29 October 2026

The people side in the United Kingdom

Get the briefing

Deals into Europe lists public facts with their sources, checked every working day by Octagon Professionals International. Corrections go to info@octagon.nl and are made within one working day. How we track deals.

Enabling organisations to operate across borders with clarity, compliance, and trust.

All deals into Europe